Indication
Platinum-sensitive Ovarian Cancer
3 clinical trials
4 products
Clinical trial
A Multi-center, Open-label, Phase I/Ib Study to Assess the Safety, Pharmacokinetics and Anti-tumor Activity of RP12146, a Poly (ADP-ribose) Polymerase (PARP) Inhibitor, in Patients With Locally Advanced or Metastatic Solid TumorsStatus: Completed, Estimated PCD: 2024-04-25
Product
RP12146Clinical trial
Randomized Phase II Study Comparing Neo-epitope Based Vaccine OSE2101 (TEDOPI®) With or Without Anti-PD1 (Pembrolizumab) Versus Best Supportive Care as Maintenance Treatment in Platinum-sensitive Recurrent Ovarian Cancer Patient With Controlled Disease After Platinum-based ChemotherapyStatus: Recruiting, Estimated PCD: 2025-12-01
Product
OSE2101Product
PembrolizumabClinical trial
Statin Therapy to Reduce Progression in Women With Platinum Sensitive Ovarian CancerStatus: Recruiting, Estimated PCD: 2024-09-01
Product
Simvastatin